For many patients, the ringing in their ears begins long before the chemotherapy bag is empty. Ototoxicity, the hearing and balance damage caused by platinum-based cancer drugs like cisplatin, is a well-documented but stubbornly difficult side effect to manage. It can manifest as irreversible hearing loss, tinnitus, or vertigo, adding a layer of sensory isolation to an already grueling treatment journey. In Houston, a new medtech startup called Akomera is prototyping a device that aims to intervene at the precise moment the damage is done, during the infusion itself [F6S, January 2026].
A bet on localized protection
Akomera’s core proposition is a noninvasive, locally targeted wearable designed for patients to use during their chemotherapy sessions [F6S, January 2026]. The clinical rationale is straightforward: if the ototoxic agent is most concentrated and damaging as it enters the bloodstream, a countermeasure applied directly at the site and time of infusion could theoretically offer the most potent protection. This approach differs from existing strategies, which are largely reactive. The current standard involves post-treatment audiological monitoring and, if damage is detected, rehabilitation with hearing aids. Akomera’s bet is that prevention, delivered in the clinic, is a more humane and potentially more effective path. Founder Sarah Kusumo, a biomedical engineer with a background in medical device R&D at Medtronic, is leading the early prototyping and intellectual property work from within the Texas Medical Center ecosystem [LinkedIn, September 2026].
Early validation within the Texas Medical Center
The company’s trajectory so far is a classic story of institutional incubation. Akomera has raised a reported $70,000 from the Texas Medical Center and Kusumo has progressed through its founder-in-residence program [F6S, September 2026]. Further validation came from selection into the 2026 cohorts of both the MedTech Innovator accelerator and the TiE Houston founder program [TiE Houston, July 2026] [LinkedIn, September 2026]. These programs provide mentorship and pitch coaching, but more importantly, they signal that experienced judges in the medtech field see merit in the underlying clinical problem. The company’s stated focus is now on advancing its prototype while developing the crucial regulatory and reimbursement strategies that will dictate its commercial future [F6S, January 2026].
The competitive and clinical landscape
The market Akomera is entering is defined by a significant unmet need but also by established, if imperfect, alternatives. The severity of ototoxicity varies, influenced by the patient’s age, the specific drug, and its dosage, but its impact on quality of life is consistently profound [PMC, 2026]. Currently, the landscape for addressing this toxicity splits into two main approaches.
- Pharmaceutical intervention. Companies like Fennec Pharmaceuticals have pursued FDA-approved drugs, such as sodium thiosulfate, which is administered intravenously to neutralize cisplatin after it has circulated. This is a systemic treatment with its own administration complexity.
- Rehabilitation and monitoring. Firms like Sensorion focus on therapies and diagnostics for hearing disorders, operating largely in the post-damage space of therapeutic development and auditory testing.
Akomera’s wedge is its form factor and timing. By being noninvasive, wearable, and used only during the infusion, it seeks to avoid the burdens of additional IV drugs or lifelong assistive devices. The table below outlines the contrasting approaches.
| Company | Approach | Stage | Primary Focus |
|---|---|---|---|
| Akomera | Noninvasive wearable device | Pre-seed, prototyping | Prevention during infusion |
| Fennec Pharmaceuticals | IV chemoprotectant drug | Commercial, FDA-approved | Systemic neutralization post-infusion |
| Sensorion | Gene therapies & diagnostics | Clinical & commercial | Treatment & diagnosis of existing hearing loss |
The long road to the clinic
The ambition is clear, but the path for a novel hardware device in oncology is among the most rigorous in medicine. Akomera’s primary challenges are not just technical but procedural. The device will require clearance from the U.S. Food and Drug Administration, likely through the de novo or 510(k) pathway, which demands robust clinical data demonstrating safety and a reasonable assurance of effectiveness. Generating that data will necessitate controlled clinical trials, a process that is expensive, time-consuming, and requires deep clinical partnerships. Furthermore, the company must build a compelling economic case for hospitals and insurers, proving that preventing hearing damage saves the healthcare system money in the long run by avoiding the costs of audiological care, hearing aids, and associated patient morbidity.
For patients receiving platinum-based chemotherapy, the standard of care today is largely defined by vigilance and adaptation. Oncologists are aware of the risk, and patients typically undergo baseline hearing tests before treatment and monitoring afterwards. When hearing loss occurs, as it does for a significant portion of patients, the primary interventions are hearing aids and auditory rehabilitation,tools for managing a deficit, not preventing it. Akomera’s entire thesis rests on shifting that paradigm from management to protection, offering a shield during the battle rather than just a repair once the battle is over. The next twelve months will be critical for the young company as it moves from accelerator demonstrations to generating the first preclinical data that can attract the larger seed funding required for the long clinical march ahead.